ITM and POINT Biopharma expand supply agreement for lutetium-177

ITM Isotope Technologies Munich SE and POINT Biopharma Global Inc. expanded their global supply agreements for non-carrier-added lutetium-177 (n.c.a. 177Lu) to support POINT's clinical and commercial development. Financial details were not disclosed.

“The expanded agreement broadens the supply of ITM's non-carrier-added lutetium-177 (n.c.a. 177 Lu) to POINT to enable its usage in the clinical and potential future commercial development of the 177 Lu-based molecules in POINT's development pipeline.”itm-radiopharma.com

• 1 source
• itm-radiopharma.comITM Radiopharma: ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177Jul 31, 2023

Summarized from public sources; check the original articles before acting on it.